C3181260_interactsWith_C3529352 | Knowledge4COVID-19

Property	Value
?:effect	<https://research.tib.eu/covid-19/entity/C0001688>
?:hasPrimarySource	<https://research.tib.eu/covid-19/SourceName/UMLS>
?:impact	increase
?:interaction	The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Evolocumab.
?:objectDrug	<https://research.tib.eu/covid-19/entity/C3529352>
?:object_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB09303>
?:precipitantDrug	<https://research.tib.eu/covid-19/entity/C3181260>
?:precipitant_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB05209>
is ?:subClassOf of	<https://research.tib.eu/covid-19/entity/C3181260_hasPharmacodynamic_C3529352>
?:type	<https://research.tib.eu/covid-19/vocab/DrugDrugInteraction>

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic>	<https://research.tib.eu/covid-19/entity/C0024002_interactsWith_C0010552>
<http://xmlns.com/foaf/0.1/topic>	Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>	<https://research.tib.eu/covid-19/data/entity/C0024002_interactsWith_C0010552>
<http://purl.org/net/provenance/ns#createdBy>	Anon_1

expand all